• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, November 17, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Multiple sclerosis: Endogenous retrovirus HERV-W key to nerve tissue damage

Bioengineer by Bioengineer
June 27, 2019
in Health
Reading Time: 2 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Neurology: Publication in PNAS

IMAGE

Credit: HHU / Joel Gruchot / Patrick Küry

Early disease stages of MS are primarily characterised by immune cell infiltration of the CNS. This causes inflammation that damages the so-called myelin sheaths. Myelin sheaths are electrically insulating structures established by specialised glial cells of the CNS, referred to as ‘oligodendrocytes’. These structures protect, nourish and stabilise axons, which transmit electrical signals between neurons.

There is a large therapeutic repertoire of immunomodulatory drugs available that can effectively target the inflammatory aspects of relapsing multiple sclerosis (RMS). But when MS progresses, damage accumulates which ultimately results in irreversible deficits and clinical disability. Unfortunately, despite decades of intense research disease progression is still untreatable as there are no therapies available that either prevent damage or repair injured axons.

In a new study published online on June 18 in the renowned journal PNAS a research team led by Prof. Dr. Patrick Küry from the Department of Neurology (chaired by Prof. Dr. Hans-Peter Hartung) has shed light on a novel axon damage mechanism which could be highly relevant for progressive MS (PMS) patients.

As outlined by the first author of this research paper, Dr. David Kremer, the envelope (ENV) protein of the pathogenic human endogenous retrovirus type W (pHERV-W) was found to be a major contributor to nerve damage in MS. In collaboration with research teams in Cleveland (OH, USA) and Montreal (CAN) the authors demonstrated that the ENV protein drives CNS resident microglial cells to contact and damage myelinated axons.

Alongside the scientific research into determining how the damage mechanism works, clinical developments aiming at neutralising the harmful ENV protein in MS patients have also progressed. Two clinical studies conducted under the supervision of Prof. Hartung have already successfully tested the ENV-neutralising antibody temelimab. MRI scans of the participants treated in the study showed reduced damage to the nerve tissue.

The Düsseldorf-based researchers and their colleagues can therefore explain why neurodegeneration is decreased in patients treated with temelimab. This antibody specifically binds to the ENV protein of the retrovirus and blocks its activity in the CNS. As stated by Prof. Hartung, future clinical studies in progressive MS patients will now have to demonstrate whether temelimab treatment can also improve clinical symptoms resulting from neurodegeneration.

###

Original publication

Kremer D, Gruchot J, Weyers V, Oldemeier L, Göttle P, Healy L, Ho Jang J, Kang T Xu Y, Volsko C, Dutta R, Trapp BD, Perron H, Hartung HP, Küry P., pHERV-W envelope protein fuels microglial cell-dependent damage of myelinated axons in multiple sclerosis, Proc. Natl. Acad. Sci. U. S. A. 2019 Jun 18. pii: 201901283

Media Contact
Dr. Arne Claussen
arne.claussen@hhu.de

Related Journal Article

http://dx.doi.org/10.1073/pnas.1901283116

Tags: BiologyMedicine/Healthneurobiology
Share13Tweet8Share2ShareShareShare2

Related Posts

Study Finds Postmarketing Cardiac and Urticaria Safety Signals for Pericarditis Drug Rilonacept

Study Finds Postmarketing Cardiac and Urticaria Safety Signals for Pericarditis Drug Rilonacept

November 17, 2026
Higher Body Mass Index Linked to Reduced Osteoporosis Risk

Higher Body Mass Index Linked to Reduced Osteoporosis Risk

November 17, 2026

Five Clinical Factors Predict Diabetic Retinopathy Risk in Type 2 Diabetes

November 17, 2026

Abdominal CT Radiomics Identifies Prevalent Heart Disease in Type 2 Diabetes

November 17, 2026
Please login to join discussion

POPULAR NEWS

  • Five Clinical Factors Predict Diabetic Retinopathy Risk in Type 2 Diabetes

    Five Clinical Factors Predict Diabetic Retinopathy Risk in Type 2 Diabetes

    29 shares
    Share 12 Tweet 7
  • Abdominal CT Radiomics Identifies Prevalent Heart Disease in Type 2 Diabetes

    29 shares
    Share 12 Tweet 7
  • Researchers Propose D-Allulose Framework to Test Metabolic Signaling and Aging

    29 shares
    Share 12 Tweet 7
  • Gut Microbiome Shifts Linked to Depressive Symptoms in Diabetes Patients

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Two-Scale Perturbation Models Accelerate Offshore Wind Farm Atmospheric Blockage Predictions

Grid-Powered Desalination Refill Eliminates Modeled Freshwater Shortages in Istria Study

Study Finds Postmarketing Cardiac and Urticaria Safety Signals for Pericarditis Drug Rilonacept

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.